Stem Cell Therapeutics says NTx-265 repairs lost neurological function

By Elaine Rigoli

Tampa, Fla., Aug. 15 - Stem Cell Therapeutics Corp. said new data in test animals suggests that treatment with NTx-265 regimen of drugs produces substantial and significant recovery of lost neurological function.

NTx-265 is a peripherally administered proprietary dose and schedule of human chorionic gonadotropin followed by erythropoietin.

Human chorionic gonadotropin and erythropoietin have both been marketed worldwide for years in other medical applications and extensive safety data exists for both molecules, the company noted.

Stem Cell Therapeutics is a biotechnology company based in Calgary, Alta.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.